Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.

PubWeight™: 0.97‹?› | Rank: Top 15%

🔗 View Article (PMID 16937115)

Published in Cancer Immunol Immunother on August 26, 2006

Authors

Takafumi Minami1, Satoko Matsueda, Hiroko Takedatsu, Masahiro Tanaka, Masanori Noguchi, Hirotsugu Uemura, Kyogo Itoh, Mamoru Harada

Author Affiliations

1: Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka, Japan.

Articles citing this

HLA class I supertypes: a revised and updated classification. BMC Immunol (2008) 3.47

Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer (2007) 0.92

Identification of naturally processed ligands in the C57BL/6 mouse using large-scale mass spectrometric peptide sequencing and bioinformatics prediction. Immunogenetics (2009) 0.85

Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer. J Transl Med (2009) 0.80

Intraperitoneal administration of a tumor-associated antigen SART3, CD40L, and GM-CSF gene-loaded polyplex micelle elicits a vaccine effect in mouse tumor models. PLoS One (2014) 0.78

UPDATE ON VACCINE DEVELOPMENT FOR RENAL CELL CANCER. Open Access J Urol (2010) 0.77

Update on vaccine development for renal cell cancer. Open Access J Urol (2010) 0.76

A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients. Exp Ther Med (2010) 0.75

Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma. PLoS One (2017) 0.75

Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer. Exp Ther Med (2010) 0.75

Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11(+) or -A33(+) allele. Cancer Sci (2017) 0.75

Articles by these authors

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13

Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21

Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88

NLRX1 negatively regulates TLR-induced NF-κB signaling by targeting TRAF6 and IKK. Immunity (2011) 2.10

Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol (2009) 2.03

Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma. Int J Urol (2014) 2.02

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 1.70

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66

Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res (2005) 1.65

Sorafenib rechallenge in patients with metastatic renal cell carcinoma. BJU Int (2012) 1.52

Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient. J Immunother (2005) 1.47

Effect of tamsulosin on bladder blood flow and bladder function in a rat model of bladder over distention/emptying induced bladder overactivity. J Urol (2011) 1.43

Carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress. Int J Urol (2010) 1.43

Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci (2006) 1.41

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate (2003) 1.32

Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol (2010) 1.28

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer (2011) 1.26

Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol (2010) 1.23

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol (2010) 1.18

Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem (2014) 1.17

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer (2008) 1.16

Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother (2012) 1.16

A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res (2006) 1.15

A case of primary mucosa-associated lymphoid tissue lymphoma of the prostate. Rare Tumors (2009) 1.14

Enhancement of intervertebral disc cell senescence by WNT/β-catenin signaling-induced matrix metalloproteinase expression. Arthritis Rheum (2010) 1.13

Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. PLoS One (2013) 1.11

Effect of cell number on mesenchymal stem cell transplantation in a canine disc degeneration model. J Orthop Res (2010) 1.11

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol (2013) 1.10

Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother (2008) 1.10

Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother (2012) 1.10

Next-generation peptide vaccines for advanced cancer. Cancer Sci (2012) 1.09

Interleukin-5 participates in the pathogenesis of ileitis in SAMP1/Yit mice. Eur J Immunol (2004) 1.09

A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep (2010) 1.07

Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol (2008) 1.06

STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol (2007) 1.06

Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res (2004) 1.05

Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther (2010) 1.04

Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. BJU Int (2009) 1.03

Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol (2012) 1.03

Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother (2009) 1.02

A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother (2002) 1.01

Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int (2010) 1.00

Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci (2007) 1.00

In vitro micronucleus assay for cigarette smoke using a whole smoke exposure system: a comparison of smoking regimens. Exp Toxicol Pathol (2009) 0.99

Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol (2013) 0.99

Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci (2003) 0.98

Cloning of mouse Cited4, a member of the CITED family p300/CBP-binding transcriptional coactivators: induced expression in mammary epithelial cells. Genomics (2002) 0.98

Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate (2007) 0.98

Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. J Immunother (2003) 0.98

Diphenyleneiodium (DPI) reduces oxalate ion- and calcium oxalate monohydrate and brushite crystal-induced upregulation of MCP-1 in NRK 52E cells. Nephrol Dial Transplant (2005) 0.97

Kidney Cancer Working Group report. Jpn J Clin Oncol (2010) 0.97

Multifarious control of two-photon excitation of multiple fluorophores achieved by phase modulation of ultra-broadband laser pulses. Opt Express (2009) 0.97

Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother (2011) 0.97

Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. Int J Clin Oncol (2011) 0.97

Bisphosphonate (YM529) delays the repair of cortical bone defect after drill-hole injury by reducing terminal differentiation of osteoblasts in the mouse femur. Bone (2005) 0.97

The HSP70 and autophagy inhibitor pifithrin-μ enhances the antitumor effects of TRAIL on human pancreatic cancer. Mol Cancer Ther (2013) 0.96

Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res (2005) 0.96

Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer (2010) 0.96

A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int (2010) 0.96

Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol (2002) 0.95

Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer (2011) 0.95

Role of the CD5 molecule on TCR gammadelta T cell-mediated immune functions: development of germinal centers and chronic intestinal inflammation. Int Immunol (2003) 0.94

Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther (2008) 0.94

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate (2005) 0.94

Immediate early genes expressed in chlorovirus infections. Virology (2004) 0.94

Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients. Nephrology (Carlton) (2011) 0.94

Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med (2011) 0.93

Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother (2003) 0.92

Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer (2002) 0.92

Anti-influenza virus compound from Streptomyces sp. RI18. Org Lett (2010) 0.92

A case of small cell carcinoma of the kidney. Hinyokika Kiyo (2007) 0.92

Analysis of bone mineral density in urolithiasis patients. Int J Urol (2005) 0.92

Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine (2007) 0.91

Association of tumor necrosis factor and human leukocyte antigen DRB1 alleles with Graves' ophthalmopathy. Hum Immunol (2004) 0.91

Vascular endothelial growth factor is expressed along with its receptors during the healing process of bone and bone marrow after drill-hole injury in rats. Bone (2003) 0.91